1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. Company
    ACE   SE0010573113


Business Summary
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.

Number of employees : 21 people.
Name Title Age Since
Magnus Olafsson Corfitzen Chief Executive Officer 46 2014
Kristian Borbos Chief Financial Officer 43 2017
Carl Bjartmar, Dr. Chief Medical Officer 58 2018
Mikael Widell Head-Investor Relations & Communication 63 2018
Julie Waras Brogren Chief Commercial Officer 49 2020
Members of the board
Name Title Age Since
Peter James Arthur Benson Chairman 66 2017
Bo Jesper Hansen, Dr. Independent Director 63 2010
Anna Helena Wennerstr÷m Independent Director 56 2017
Hans Maier, Dr. Independent Director 66 2017
Niels Viggo Mengel Independent Director 73 2000
RenÚ J°rgen Spogard Independent Director 67 2017
Lauren G. Barnes Independent Director - 2020
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,668,262 28,171,071 83.7% 0 0.0% 83.7%
Sunstone Capital A/S 7,425,305 22.1%
Heartcore Capital A/S 4,778,129 14.2%
Fjńrde AP-fonden 2,209,266 6.56%
ěresund-Healthcare Management A/S 2,020,490 6.00%
Handelsbanken Fonder AB 1,350,823 4.01%
Healthinvest Partners AB 1,200,000 3.56%
Lansforsakringar Fonder 1,191,756 3.54%
Lńnsf÷rsńkringar Fondf÷rvaltning AB 1,129,986 3.36%
RenÚ J°rgen Spogard 1,004,733 2.98%
Ostvast Capital Management 950,000 2.82%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Ascelia Pharma AB (publ)